case
rhinosinus
caus
viral
upper
respiratori
tract
infect
infect
lead
inflamm
edema
caus
obstruct
sinu
ostia
decreas
mucociliari
clearanc
sinus
effect
creat
condit
favor
bacteri
growth
estim
viral
upper
respiratori
tract
infect
becom
secondarili
infect
caus
rhinosinus
includ
anatom
deform
deviat
polyp
foreign
bodi
nasogastr
tube
allergi
direct
injuri
upper
teeth
form
fistula
lead
anaerob
growth
within
sinus
estim
maxillari
sinus
associ
dental
microbiolog
two
common
bacteri
caus
acut
sinus
streptococcu
pneumonia
nontyp
haemophilu
influenza
bacteria
account
organ
caus
acut
bacteri
moraxella
catarrhali
streptococc
speci
anaerob
caus
smaller
percentag
acut
least
half
acut
sinus
caus
rhinoviru
parainfluenza
influenza
common
viral
caus
acut
sinus
fungal
etiolog
acut
chronic
sinus
also
increasingli
reogniz
common
organ
isol
chronic
sinus
staphylococcu
epidermidi
staphylococcu
aureu
streptococcu
pneumonia
sixteen
percent
chronic
sinus
caus
multipl
organ
organ
found
chronic
sinus
includ
streptococcu
viridan
h
influenza
gramnega
tive
diagnosi
sinus
usual
base
clinic
find
howev
ill
allerg
rhiniti
may
present
similarli
common
symptom
acut
rhinosinus
includ
purul
nasal
discharg
facial
pain
congest
cough
fever
symptom
specif
ns
specif
symptom
sinus
maxillari
toothach
symptom
limit
patient
studi
william
find
purul
penicillin
pcn
cephalosporin
pcn
v
mg
po
pcn
g
mu
iv
amoxicillin
mg
po
tid
ampicillin
g
mg
iv
amoxicillinclavulan
augmentin
mg
po
tid
po
bid
ampicillinsulbactam
unasyn
g
iv
upper
respiratori
tract
symptom
account
major
primari
care
physician
offic
visit
symptom
may
caus
common
cold
sinus
term
rhinosinus
develop
includ
full
spectrum
common
cold
sinus
inflamm
infect
paranas
sinus
year
million
case
acut
sinus
million
case
chronic
sinus
unit
sinus
categor
acut
chronic
base
durat
symptom
acut
sinus
symptom
may
last
week
chronic
sinus
symptom
may
persist
week
despit
optim
medic
therapi
period
time
week
less
well
defin
author
classifi
symptom
period
subacut
sinus
color
nasal
discharg
maxillari
toothach
poor
respons
nasal
decongest
abnorm
transillumin
best
predictor
sinus
physic
examin
usual
reveal
sinu
mucos
edema
postnas
drainag
sinu
tender
howev
none
find
specif
sinus
often
difficult
distinguish
viral
upper
respiratori
tract
infect
bacteri
sinus
first
day
symptomat
ill
worsen
symptom
day
persist
symptom
day
sever
initi
present
may
suggest
bacteri
laboratori
studi
nasal
swab
cultur
usual
recommend
evalu
acut
sinus
patient
chronic
recurr
sinus
may
need
sinu
endoscopi
evalu
sinu
anatomi
obtain
bacteriolog
cultur
immunodefici
evalu
consid
patient
respond
appropri
therapi
plain
sinu
film
often
obtain
evalu
sinus
film
usual
includ
four
view
sinu
one
recent
studi
suggest
singl
water
view
occipitoment
view
may
substitut
fourview
seri
three
radiograph
criteria
use
diagnosi
sinus
thicken
mucosa
greater
mm
airfluid
level
opacif
sinu
caviti
disadvantag
sinu
film
includ
poor
visual
ethmoid
air
space
inabl
differenti
tumor
polyp
infect
sinu
ct
scan
gold
standard
radiograph
imag
sinus
howev
scan
use
routin
evalu
acut
sinus
main
role
help
defin
sinu
anatomi
possibl
surgeri
definit
diagnosi
acut
sinus
pierc
sinus
cultur
extract
materi
impract
offic
use
symptomat
therapi
often
initi
therapi
sinus
support
therapi
increas
fluid
intak
nasal
salin
spray
enhanc
moist
environ
recommend
decongest
topic
phenylephrin
neosynephrin
oxymetazolin
afrin
use
vasoconstrict
local
blood
vessel
decreas
edema
howev
use
topic
decongest
day
recommend
practic
lead
rebound
vasodilat
rhiniti
medicamentosa
system
decongest
provid
symptomat
relief
side
effect
nervous
tachycardia
hypertensionu
common
adjunct
therapi
proven
efficaci
may
help
patient
therapi
includ
mucolyt
guaifenesin
antihistamin
nasal
steroid
spray
latter
two
therapi
may
help
patient
allergi
sympt
mild
case
acut
sinus
adjunct
therapi
may
use
alon
least
one
third
patient
viral
sinus
studi
show
good
respons
placebo
antimicrobi
regimen
furthermor
antibiot
affect
durat
relaps
rate
acut
sinus
symptom
sinus
persist
day
caus
like
bacteri
infect
empir
antibiot
therapi
activ
common
caus
organ
pneumoniu
h
influenza
cuturrhuli
select
antibiot
also
depend
antibiot
resist
pattern
commun
rate
penicillin
pcn
resist
h
inflluenzu
infect
may
reach
wherea
rate
pcnresist
cuturrkuli
infect
may
reach
increas
rate
multidrugresist
preumoniu
even
increas
pcn
resist
common
caus
agent
mani
expert
still
recommend
amoxicillin
firstlin
therapi
acut
sinus
owe
narrow
spectrum
side
effect
low
cost
trimethoprim
sulfamethoxazol
tmpsmx
use
firstlin
therapi
patient
pcn
allergi
patient
respond
firstlin
therapi
day
regimen
chang
cover
betalactamaseproduc
h
influenzu
pcnresist
streptococcu
recommend
secondlin
agent
acut
sinus
amoxicillinclavulan
secondor
thirdgener
cephalosporin
cefuroxim
axetil
cefpodoxim
proxetil
loracarbef
newer
macrolid
azithromycin
clarithromycin
fluoroquinolon
gatifloxacin
moxifloxacin
levofloxacin
clindamycin
also
activ
pcnresist
pneumoniu
durat
treatment
acut
sinus
usual
recommend
support
two
set
guidelin
manag
sinu
addit
set
guidelin
recommend
sinu
allergi
partnership
advoc
use
amoxicillin
clavulan
cefpodoxim
praxetil
cefuroxim
axetil
initi
agent
discourag
use
tmpsmx
antibiot
chronic
sinus
activ
staphylococc
speci
betalactamaseproduc
secondlin
agent
use
acut
sinus
also
affect
treatment
chronic
sinus
firstlin
agent
recommend
owe
higher
rate
bacteri
resist
chronic
sinus
metronidazol
clindamycin
ad
initi
agent
activ
anaerob
patient
respond
day
total
durat
antimicrobi
therapi
chronic
sinus
week
endoscop
sinu
cultur
may
obtain
patient
chronic
sinus
higher
incid
multipl
organ
resist
antibiot
indic
surgic
intervent
includ
complic
sinus
local
spread
infect
nearbi
structur
eye
brain
treatment
failur
two
cours
antibiot
frequent
recurr
three
episod
per
year
nosocomi
infect
sinus
immunocompromis
host
pharyng
inflamm
infect
nasopharynx
ropharynx
primarili
childhood
ill
also
affect
adult
especi
winter
earli
case
pharyng
caus
virus
one
must
differenti
viral
bacteri
caus
pharyng
bacteri
pharyng
caus
group
streptococcu
seriou
complic
treat
appropri
virus
caus
least
pharyng
common
viru
caus
pharyng
rhinoviru
follow
coronaviru
adenoviru
parainfluenza
influenza
viru
often
difficult
differenti
viral
bacteri
pharyng
patient
viral
pharyng
usual
nonspecif
flulik
symptom
fever
malais
myalgia
patient
pharyng
owe
rhinoviru
usual
present
nasal
symptom
primari
complaint
mildtomoder
sore
viral
agent
adenoviru
ebv
cmv
herp
simplex
viru
may
caus
sever
pharyng
resembl
group
streptococc
virus
caus
selflimit
ill
resolv
within
week
physic
examin
may
vari
degre
pharyng
erythema
without
exud
specif
featur
viral
pharyng
help
present
find
includ
adenovir
conjunct
herpet
vehicl
lymphadenopathi
splenomegali
associ
ebvmononcleosi
patient
streptococc
pharyng
may
complain
pharyng
pain
odynophagia
headach
fever
physic
examin
may
reveal
erythema
exud
pharynx
tonsil
uvular
edema
tender
lymphadenopathi
one
may
also
find
maculopapular
rash
associ
scarlet
fever
red
enlarg
tongu
known
strawberri
tongu
find
specif
group
streptococc
pharyng
bacteri
caus
group
c
streptococcu
present
similarli
anaerob
infect
may
present
purul
exud
foul
odor
pharyng
pain
diphtheria
characterist
pharyng
gray
membran
firmli
attach
pharynx
find
may
help
diagnosi
bacteri
pharyng
diagnosi
group
streptococc
pharyng
usual
confirm
laboratori
test
throat
cultur
gold
standard
identifymg
streptococc
proper
specimen
collect
sensit
test
cultur
take
hour
confirm
may
result
unnecessari
delay
antibiot
administr
test
result
falseneg
test
rapid
antigen
detect
test
radt
develop
diagnos
streptococc
pharyng
outpati
clinic
within
minut
howev
conveni
test
offset
higher
cost
low
sensit
neg
radt
rule
streptococc
pharyng
must
confirm
streptococc
cultur
fig
posit
radt
highli
correl
streptococc
pharyng
specif
antistreptococc
antibodi
titer
role
detect
acut
streptococc
pharyng
titer
reflect
past
infect
treatment
viral
pharyng
mainli
support
adequ
hydrat
antipyret
analges
salin
gargl
newer
therapi
amantadin
rimantadin
neuraminidas
inhibitor
may
help
given
earli
cours
ill
pcn
continu
mainstay
therapi
streptococc
pharyng
report
case
pcn
resist
among
group
streptococcusl
cours
pcn
v
singl
inject
benzathin
pcn
suffici
treat
prevent
complic
group
streptococc
patient
allerg
pcn
treat
cours
erythromycin
although
failur
rate
may
newer
macrolid
secondgener
cephalosporin
cefuroxim
cefixim
amoxillinclavulan
also
use
common
caus
bacteri
pharyng
may
treat
similarli
pcn
recurr
group
streptococc
pharyng
may
occur
owe
noncompli
reinfect
close
contact
viral
infect
streptococcu
second
cours
antibiot
benzathin
pcn
may
help
ensur
complianc
treat
close
contact
posit
streptococc
radt
repeat
throat
cultur
may
also
necessari
patient
complic
group
streptococc
pharyng
sever
lifethreaten
direct
complic
peritonsillar
abscess
scarlet
fever
requir
hospit
treatment
intraven
antibiot
immunolog
consequ
group
streptococc
infect
occur
resolut
acut
infect
ill
immun
complexmedi
treat
antibiot
hallmark
immunemedi
poststreptococc
diseas
acut
rheumat
fever
acut
glomerulonephr
acut
rheumat
fever
common
complic
group
streptococc
pharyng
pcn
therapi
recent
rise
incid
complic
alert
clinician
diagnos
group
streptococc
pharyng
acut
rheumat
fever
typic
occur
week
pharyng
diagnos
use
jone
criteria
item
includ
major
criteria
carditi
migratori
polyarthr
sydenham
chorea
subcutan
nodul
erythema
marginatum
minor
criteria
includ
arthralgia
fever
prolong
pr
interv
elev
sediment
rate
creactiv
protein
acut
glomerulonephr
occur
mostli
children
day
onset
treatment
acut
glomerulonephr
mainli
support
acut
bronchiti
affect
us
popul
annual
rank
fifth
among
common
caus
outpati
offic
visitsl
acut
bronchiti
inflamm
tracheobronchi
tree
caus
bronchial
edema
increas
mucu
j
often
precipit
viral
infect
usual
occur
winter
respiratori
infect
case
acut
bronchiti
healthi
adult
caus
viral
infect
ratio
viral
bacteri
etiolog
known
common
virus
caus
acut
bronchiti
influenza
adenoviru
respiratori
syncyti
viru
rsv
rhinovirusl
coxsackieviru
coronaviru
measl
herp
viru
also
caus
acut
bronchiti
bacteri
pathogen
known
associ
acut
bronchiti
otherwis
healthi
adult
pneumonia
c
pneumonia
bordetella
pneumonia
h
influenza
may
also
caus
agent
link
controversi
noninfecti
etiolog
allergi
air
pollut
also
trigger
acut
bronchiti
trigger
caus
inflamm
tracheobronchi
tree
result
increas
secret
impair
mucociliari
clearanc
increas
airway
reactiv
main
present
symptom
acut
bronchiti
cough
without
sputum
product
although
cough
usual
subsid
day
may
persist
week
nonspecif
flulik
symptom
fever
chill
malais
may
also
present
symptom
usual
resolv
within
day
lower
airway
involv
patient
may
experi
pleurit
chest
pain
hemoptysi
dyspnea
usual
associ
acut
bronchiti
unless
patient
underli
cardiopulmonari
diseas
physic
examin
find
consist
reactiv
airway
diseas
wheez
may
heard
rale
rhonchi
may
also
present
may
local
decreas
breath
sound
focal
atelectai
none
find
specif
acut
bronchiti
therefor
may
difficult
differenti
acut
bronchiti
seriou
ill
lower
respiratori
tract
thorough
histori
physic
examin
help
differenti
acut
bronchiti
caus
cough
sinus
reflux
asthma
cardiovascular
diseas
pulmonari
diseas
pneumonia
embol
laboratori
test
sputum
gram
stain
may
help
predomin
organ
seen
sputum
cultur
usual
help
owe
contamin
nasopharyng
flora
difficulti
interpret
moreov
acut
bronchiti
often
caus
viral
infect
sputum
cultur
serolog
studi
mycoplasma
chlamydia
obtain
agent
suspect
patient
sever
persist
symptom
evalu
chest
radiographi
complet
blood
count
puls
oximetri
blood
ga
rule
seriou
caus
respiratori
ill
case
acut
bronchiti
caus
viral
rather
bacteri
infect
antibiot
usual
recommend
nevertheless
studi
show
half
patient
acut
bronchiti
treat
antibiot
practic
encourag
develop
antimicrobi
resist
increas
risk
antimicrobialrel
side
effect
patient
treat
symptomat
hydrat
cough
suppress
antipyret
analges
bronchodil
may
help
patient
bronchspasm
amantadin
rimantadin
new
neuraminidas
inhibitor
shorten
durat
decreas
sever
symptom
viral
infect
given
first
hour
symptomat
influenza
ill
influenza
pneumococc
vaccin
also
invalu
prevent
ill
antibiot
consid
patient
extrem
age
signific
underli
medic
diseas
present
sever
persist
antibiot
activ
predomin
bacteri
organ
c
pneumonia
pneumonia
bordetella
pertussi
tetracyclin
doxycyclin
tmpsmx
macrolid
provid
adequ
coverag
organ
acut
bronchiti
common
entiti
affect
mani
person
otherwis
healthi
appropri
diagnosi
base
clinic
find
exclus
seriou
ill
antibiot
usual
necessari
treatment
acut
bronchiti
instead
symptomat
therapi
mainstay
treatment
selflimit
ill
acut
exacerb
chronic
bronchiti
aecb
occur
patient
chronic
bronchiti
present
acut
worsen
respiratori
symptom
patient
may
present
increas
cough
sputum
product
wheez
unlik
acut
bronchiti
treatment
aecb
usual
warrant
antibiot
antibiot
chosen
activ
common
caus
organ
h
influenza
pneumonia
moraxella
atarrhali
viral
agent
atyp
may
also
role
treat
exacerb
antibiot
recommend
treatment
aecb
includ
secondgener
cephalosporin
cefuroxim
cefpodoxim
newer
macrolid
azithromycin
clarithromycin
quinolon
amoxicillinclavulan
may
appropri
patient
moderatetosever
chronic
obstruct
pulmonari
diseas
copd
comorbid
ill
adjunct
therapi
bronchodil
anticholinerg
betaagonist
oxygen
may
ad
underli
pulmonari
diseas
communityacquir
pneumonia
cap
sixth
common
caus
death
unit
total
death
attribut
cap
annual
unit
state
death
occur
patient
underli
diseas
requir
hospit
cap
sever
organ
publish
guidelin
help
primari
care
physician
manag
cap
american
thorac
societi
guidelin
infecti
diseas
societi
america
guidelin
patient
pneumonia
often
present
cough
dyspnea
purul
sputum
pleurit
chest
pain
system
sign
infect
includ
fever
chill
nightsweat
fatigu
physic
examin
patient
may
fever
increas
respiratori
rate
sign
consolid
pleural
effus
may
present
chest
radiographi
obtain
confirm
clinic
find
pneumonia
respiratori
symptom
less
like
caus
pneumonia
absenc
consolid
falseneg
chest
film
may
seen
earli
pneumonia
dehydr
pneumocysti
carinii
pneumonia
pcp
falseposit
find
may
occur
atelectasi
pulmonari
infarct
bronchogen
carinoma
chest
radiograph
help
assess
sever
howev
alway
possibl
obtain
chest
radiograph
outpati
set
laboratori
studi
sputum
gram
stain
cultur
may
obtain
look
predomin
contamin
upper
respiratori
tract
organ
may
lower
yield
sputum
studi
invalu
stain
acidfast
bacilli
fungi
pcp
select
patient
popul
invas
procedur
bronchoscopi
usual
necessari
unless
patient
sever
ill
serolog
studi
atyp
pneumonia
recommend
initi
evalu
patient
cap
may
help
epidemiolog
purpos
ancillari
laboratori
test
includ
puls
oximetri
complet
blood
count
chemistri
help
assess
sever
pneumonia
patient
requir
hospit
undergo
addit
test
arteri
blood
ga
blood
cultur
hiv
test
patient
year
old
sever
pneumonia
thoracentesi
perform
rule
empyema
pleural
effus
p
r
ee
n
even
extens
diagnost
test
pathogen
found
least
one
third
patient
observ
reflect
difficulti
obtain
good
respiratori
specimen
isol
organ
common
caus
cap
pneumonia
follow
h
influenza
atyp
organ
gramneg
organ
aureu
viral
agent
account
influenza
common
caus
viral
pneumonia
virus
parainfluenza
rsv
adenoviru
also
associ
tuberculosi
pcp
common
caus
cap
especi
immunocompromis
patient
caus
agent
often
identifi
immedi
case
cap
treat
empir
select
antibiot
depend
patient
popul
need
hospit
outpati
younger
year
without
comorbid
ill
like
pneumonia
caus
pneurnonia
h
influenza
pneumonia
c
pneumonia
antibiot
choic
patient
includ
macrolid
azithromycin
clarithromycin
newer
fluoroquinolon
levofloxacin
sparfloxacin
grepafloxacin
doxycyclin
amoxicillinclavulan
also
recommend
commun
pcn
resist
preval
amoxicillin
secondgener
cephalosporin
cefpodoxim
cefprozil
cefuroxim
use
initi
therapi
patient
older
year
comorbid
ill
requir
hospit
like
pneumonia
caus
pneumonia
h
influenza
gramneg
organ
aweu
recommend
antibiot
group
patient
includ
secondor
thirdgener
cephalosporin
betalactam
betalactamas
inhibitor
combin
macrolid
altern
newer
quinolon
use
alon
good
activ
organ
tabl
patient
underli
structur
lung
diseas
addit
antipseudomon
coverag
agent
ciprofloxacin
patient
aspir
pneumonia
also
treat
antianaerob
agent
decis
admit
patient
hospit
one
import
step
evalu
cap
approxim
patient
cap
hospit
mortal
rate
outpati
approxim
wherea
patient
requir
hospit
morpati
certain
risk
factor
prone
complic
risk
factor
includ
age
greater
year
comorbid
ill
copd
diabet
mellitu
renal
liver
diseas
congest
heart
failur
alcohol
abus
malnutrit
immunocompromis
mani
clinic
find
associ
poor
outcom
includ
respiratori
rate
greater
breath
per
minut
diastol
blood
pressur
less
mm
hg
systol
blood
pressur
less
mm
hg
temperatur
greater
f
mental
statu
chang
laboratori
find
associ
wors
prognosi
includ
white
blood
count
less
x
greater
x
neutropenia
less
mm
hg
greater
mm
hg
room
air
hematocrit
less
abnorm
renal
function
multipl
lobe
involv
pleural
effus
chest
radiographi
evid
sepsi
dissemin
intravascular
coagul
taliti
rate
reach
specif
recommend
regard
durat
therapi
cap
gener
patient
bacteri
cap
treat
week
atyp
caus
cap
may
requir
longer
cours
therapi
last
day
immunocompromis
patient
may
also
need
longer
cours
therapi
otherwis
healthi
patient
fever
leukocytosi
usual
resolv
within
day
abnorm
physic
find
usual
resolv
within
day
chest
radiograph
may
take
longer
normal
gener
resolv
e
e
k
mani
reason
therapeut
failur
patient
may
noninfecti
ill
pulmonari
infarct
granulomat
diseas
organ
may
resist
antibiot
chosen
patient
may
complic
pneumonia
empyema
metastat
abscess
fail
respond
antibiot
patient
may
need
evalu
thoracentesi
bronchoscopi
communityacquir
pneumonia
common
infecti
ill
lead
signific
morbid
mortal
prompt
diagnosi
appropri
treatment
greatli
improv
patient
outcom
pneumonia
caus
pneurnonia
legionella
pneurnonia
c
pneurnonia
often
refer
atyp
classif
stem
earli
observ
patient
pneumonia
present
differ
patient
pneumococc
establish
often
distinguish
clinic
radiolog
featur
differenti
atyp
pneumonia
bacteri
furthermor
diagnost
laboratori
test
alway
readili
avail
therefor
often
difficult
diagnos
atyp
pneumonia
mycoplasm
pneumonia
often
consid
classic
atyp
pneumonia
clinic
patient
present
prolong
cough
last
week
constitut
symptom
headach
malais
myalgia
sore
throat
often
present
extrapulmonari
manifest
rash
gastrointestin
neurolog
symptom
also
seen
onset
symptom
usual
insidi
selflimit
physic
examin
may
normal
may
reveal
scatter
rale
definit
laboratori
diagnosi
often
difficult
owe
delay
antibodi
product
slow
growth
mycoplasma
cultur
increas
cold
agglutinin
titer
may
suggest
specif
mycoplasma
radiograph
find
variabl
may
show
peribronchi
infiltr
patient
present
sign
symptom
suggest
mycoplasm
pneumonia
treat
tetracyclin
macrolid
fluoroquinolon
week
prevent
recrrenc
legionella
intracellular
organ
caus
approxim
cap
pneumonia
hospit
legionnair
diseas
becam
well
recogn
outbreak
pneumonia
legionnair
convent
philadelphiaffi
sinc
case
legionellosi
report
northeast
great
lake
area
risk
factor
legionnair
diseas
includ
increas
age
smoke
pulmonari
renal
liver
dysfunct
transplant
recipi
patient
impair
cellmedi
clinic
patient
present
similar
fashion
patient
bacteri
pneumonia
symptom
may
rang
mildtosever
respiratori
diseas
usual
includ
high
fever
headach
myalgia
mildli
product
cough
pleurit
chest
pain
hemoptysi
diarrhea
may
present
case
chest
radiographi
usual
show
lobar
infiltr
pleural
effus
one
third
laboratori
find
suggest
legionella
includ
hyponatremia
less
mmoll
lactat
dehydrogenas
ldh
greater
rapid
diagnost
test
legionella
avail
diagnost
studi
choic
urinari
antigen
assay
legionella
serogroup
account
legionnair
test
legionella
consid
endem
area
patient
sever
respiratori
ill
immunocompromis
state
lack
respons
appropri
antibiot
clinic
present
suggest
legionnair
test
also
consid
patient
recent
travel
occup
exposur
water
erythromycin
drug
choic
treatment
legionnair
diseas
howev
newer
macrolid
clarithromycin
azithromycin
fewer
side
effect
better
vitro
result
quinolon
also
effect
legionella
critic
ill
patient
intens
care
unit
start
therapi
empir
higher
incid
legionnair
diseas
durat
therapi
legionnair
diseas
day
except
immunocompromis
patient
therapi
extend
day
altern
azithromycin
given
day
owe
prolong
pneumonia
identifi
caus
cap
sinc
incid
c
pneumonia
caus
cap
estim
primari
infect
occur
childhood
young
adulthood
recurr
infect
distinguish
clinic
radiolog
featur
chlamydi
pneumonia
patient
usual
present
mild
respiratori
ill
follow
subacut
cours
symptom
nonspecif
may
includ
sore
throat
hoars
headach
lowgrad
fever
cough
may
promin
sputum
product
usual
nonpurul
absent
radiolog
studi
may
normal
may
show
interstiti
infiltr
rapid
diagnost
test
avail
c
pneumonia
therefor
therapi
newer
macrolid
fluoroquinolon
tetracyclin
usual
empir
patient
suspect
chlamydi
pneumonia
virus
caus
pneumonia
age
group
common
caus
viral
pneumonia
influenza
follow
rsv
parainfluenza
viru
viral
pneumonia
progress
secondari
bacteri
pneumonia
caus
signific
morbid
associ
sever
pandem
influenza
caus
death
unit
patient
influenza
usual
symptom
cough
sore
throat
headach
myalgia
last
day
secondari
bacteri
infect
may
associ
recurr
fever
worsen
symptom
day
laboratori
studi
viral
cultur
elisa
use
immedi
diagnosi
viral
pneumonia
treatment
viral
pneumonia
mainli
support
antivir
agent
amantadin
rimantadin
inhibit
viral
replic
may
decreas
sever
durat
symptom
drug
activ
influenza
must
administ
within
first
hour
ill
newer
agent
neuraminidas
inhibitor
activ
influenza
b
zanamivir
relenza
oseltamivir
tamiflu
exampl
neuraminidas
inhibitor
recent
becom
avail
commerci
use
true
amantadin
rimantadin
neuraminidas
inhibitor
must
given
within
first
hour
ill
effect
annual
flu
vaccin
elderli
immunocompromis
health
care
worker
import
prevent
influenza
rsv
parainfluenza
viru
usual
caus
selflimit
mild
respiratori
infect
adult
treat
support
elderli
immunocompromis
patient
virus
caus
sever
lower
respiratori
tract
infect
associ
fever
cough
dyspnea
rapid
antigen
test
nasal
swab
perform
rsv
serotyp
pneumocysti
carinii
pneumonia
common
acquir
immunodefici
syndrom
aid
ill
hivposit
patient
cell
count
higher
risk
pcp
therefor
place
pcp
prophylaxi
tmpsmx
altern
agent
dapson
atovaquon
aerosol
pentamidin
use
patient
allerg
sulfa
agent
patient
pcp
usual
present
fever
dyspnea
nonproduct
cough
laboratori
featur
suggest
pcp
includ
oxygen
desatur
exercis
elev
howev
elev
ldh
neither
sensit
specif
pcp
chest
radiographi
usual
reveal
interstiti
pattern
resembl
ground
glass
appear
may
normal
least
case
definit
diagnosi
pcp
made
stain
induc
sputum
bronchoalveolar
specimen
effect
therapi
pcp
tmpsmx
altern
agent
atovaquon
pentamidin
primaquineclindamycin
use
patient
sulfa
allerg
intoler
develop
tmp
smx
steroid
ad
patient
less
mm
hg
room
air
durat
therapi
usual
day
mortal
rate
pcp
rang
vari
detail
discuss
tuberculosi
beyond
scope
articl
recent
rise
incid
increas
multidrugresist
diseas
tuberculosi
suspect
highrisk
popul
hivposit
patient
close
contact
patient
tuberculosi
immunosuppress
patient
present
cough
last
month
nightsweat
weight
loss
typic
radiograph
find
tuberculosi
includ
upper
lobe
infiltr
cavitari
lesion
howev
hivposit
patient
may
confirmatori
diagnost
studi
includ
induc
sputum
acidfast
bacillu
stain
cultur
dna
probe
polymeras
chain
reaction
mycobacterium
tuberculosi
allow
rapid
diagnosi
treatment
tuberculosi
depend
local
resist
pattern
area
incid
resist
tuberculosi
less
treatment
start
isoniazid
rifampin
pyrazinamid
week
follow
isoniazid
rifampin
week
area
higher
drug
resist
ethambutol
ad
initi
threedrug
therapi
week
final
sensit
known
isoniazid
rifampin
continu
addit
week
organ
sensit
vitamin
b
pyridoxin
usual
administ
isoniazid
prevent
peripher
neuropathi
hivposit
patient
tuberculosi
treat
month
patient
present
clinic
radiograph
featur
tuberculosi
neg
acidfast
bacillu
smear
treat
final
cultur
neg
take
week
pneumonia
may
occur
mani
pregnanc
clinic
present
diagnost
evalu
pneumonia
pregnant
nonpregn
patient
differ
howev
complic
pneumonia
may
higher
pregnanc
need
prompt
diagnosi
prevent
complic
also
potenti
fetal
risk
therapeut
agent
tabl
drug
choic
pneumonia
pregnant
patient
secondor
thirdgener
cephalosporin
erythromycin
atyp
coverag
need
two
common
caus
viral
pneumonia
pregnanc
influenza
varicella
pneumonia
antivir
agent
amantadin
use
pregnanc
safeti
well
defin
contrast
neuraminidas
inhibitor
seem
safe
use
pregnanc
influenza
vaccin
usual
necessari
normal
pregn
ny
varicella
affect
less
adult
popul
howev
increas
risk
varicella
pneumonia
primari
varicella
infect
develop
symptom
varicella
pneumonia
includ
rash
pleurit
chest
pain
dyspnea
cough
treatment
acyclovir
initi
immedi
although
acyclovir
usual
administ
pregnanc
use
associ
increas
fetal
without
treatment
mortal
varicella
pneumonia
pregnanc
may
reach
incid
tuberculosi
pregnanc
may
high
endem
treatment
tuberculosi
pregnant
nonpregn
patient
slightli
differ
isoniazid
rifampin
ethambutol
cross
placenta
shown
caus
teratogen
effect
pyrazinamid
usual
recommend
pregnanc
owe
lack
data
regard
teratogen
effect
pregnant
patient
tuberculosi
treat
month
pyridoxin
supplement
prevent
neuropathi
also
essenti
pregnant
drug
tuberculosi
safe
patient
breastfeed
howev
infant
also
take
medic
breastf
avoid
supratherapeut
concentr
pregnant
patient
posit
ppd
skin
test
without
activ
diseas
receiv
prophylaxi
isoniazid
prefer
first
trimest
therapi
pcp
pregnanc
nonpregn
patient
theoret
risk
kernicteru
neonat
pregnant
patient
treat
tmpsmx
complic
folic
acid
administ
patient
take
tmpsmx
insuffici
data
regard
safeti
dapson
use
pregnanc
howev
risk
benefit
ratio
usual
justifi
use
pregnant
patient
pcp
intoler
studi
pregnant
women
risk
b
anim
studi
risk
human
studi
adequ
anim
toxic
human
studi
risk
c
anim
studi
show
toxic
human
studi
inadequ
benefit
may
exceed
risk
evid
human
risk
benefit
may
outweight
unknown
barn
allerg
tmpsmx
parenter
pentamidin
sever
undesir
toxic
includ
rash
neutropenia
thrombocytopenia
use
restrict
sever
case
pcp
aerosol
pentamidin
prophylaxi
safe
use
pregnanc
respiratori
tract
infect
caus
nearli
half
death
owe
infecti
diseas
unit
state
articl
discuss
manag
sever
common
respiratori
tract
infect
emphasi
appropri
diagnosi
use
antimicrobi
agent
understand
caus
variou
respiratori
tract
infect
enabl
primari
care
physician
avoid
unnecessari
antibiot
use
decreas
advers
effect
owe
medic
prevent
rise
antimicrobi
resist
